Current Hypertension Reports

, Volume 7, Issue 1, pp 44–51 | Cite as

Inflammation, blood pressure, and stroke: an opportunity to target primary prevention?

  • Mario Di Napoli
  • Francesca Papa


Promising findings suggest that systemic inflammation and neuroinflammation are central features in cerebrovascular disease. Inflammatory mechanisms are also important participants in the pathophysiology of hypertension. Markers of inflammation have been shown to be upregulated in different forms of cerebrovascular disease, and to correlate with vascular risk. The inhibitor nuclear factor-eB/nuclear factor-eB system is considered a major intracellular inflammatory pathway, mediating most of the vascular inflammatory responses. Increasing evidence indicates that hypertension, through the vasoactive peptides angiotensin and endothelin-1, promotes and accelerates the atherosclerotic process via inflammatory mechanisms. Proinflammatory properties of angiotensin II have been demonstrated. The identification of useful markers of inflammation, of new therapeutic targets to interfere with these mechanisms, and the evaluation of the efficacy of anti-inflammatory treatments will allow progress in our ability to combat cerebrovascular disease and the complications of hypertension. Whether these targets will be useful in the development of risk prediction strategies or therapies for the treatment of stroke in humans is far from clear.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Vasan RS, Larson MG, Leip EP, et al.: Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet 2001, 358:1682–1686.PubMedCrossRefGoogle Scholar
  2. 2.
    Neal B, MacMahon S, Chapman N: Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists’ Collaboration. Lancet 2000, 356:1955–1964.PubMedCrossRefGoogle Scholar
  3. 3.
    Engstrom G, Hedblad B, Valind S, Janzon L: Increased incidence of myocardial infarction and stroke in hypertensive men with reduced lung function. J Hypertens 2001, 19:295–301.PubMedCrossRefGoogle Scholar
  4. 4.
    Di NapoliM, Papa F: Clinical application of C-reactive protein in stroke prevention: the bright and the dark sides of the moon. Exp Rev Neurother 2004, 4:613–622. An updated review on the use of inflammation markers in cerebrovascular disease.CrossRefGoogle Scholar
  5. 5.
    Wong TY, Szeto CC, Chow KM, et al.: Prognostic role of serum ACE activity on outcome of type 2 diabetic patients on chronic ambulatory peritoneal dialysis. Am J Kidney Dis 2002, 39:1054–1060.PubMedCrossRefGoogle Scholar
  6. 6.
    SleightP: The HOPE Study (Heart Outcomes Prevention Evaluation). J Renin Angiotensin Aldosterone Syst 2000, 1:18–20.PubMedGoogle Scholar
  7. 7.
    YusufS: From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. Am J Cardiol 2002, 89:18A-25A.PubMedCrossRefGoogle Scholar
  8. 8.
    Amar J, Ruidavets JB, Sollier CB, et al.: Relationship between C reactive protein and pulse pressure is not mediated by atherosclerosis or aortic stiffness. J Hypertens 2004, 22:349–355.PubMedCrossRefGoogle Scholar
  9. 9.
    BautistaLE: Inflammation, endothelial dysfunction, and the risk of high blood pressure: epidemiologic and biological evidence. J Hum Hypertens 2003, 17:223–230. A well-written review paper on the relationship between chronic inflammation and arterial hypertension.PubMedCrossRefGoogle Scholar
  10. 10.
    Di NapoliM, Papa F: Association between blood pressure and C-reactive protein levels in acute ischemic stroke. Hypertension 2003, 42:1117–1123. The first report on the association between inflammation markers and blood pressure levels in acute ischemic stroke. A possible role of acute hypertension after stroke as an inflammatory stimulus contributing to ischemic brain inflammation is suggested.PubMedCrossRefGoogle Scholar
  11. 11.
    Schillaci G, Pirro M, Gemelli F, et al.: Increased C-reactive protein concentrations in never-treated hypertension: the role of systolic and pulse pressures. J Hypertens 2003, 21:1841–1846.PubMedCrossRefGoogle Scholar
  12. 12.
    Engstrom G, Lind P, Hedblad B, et al.: Long-term effects of inflammation-sensitive plasma proteins and systolic blood pressure on incidence of stroke. Stroke 2002, 33:2744–2749.PubMedCrossRefGoogle Scholar
  13. 13.
    Sesso HD, Buring JE, Rifai N, et al.: C-reactive protein and the risk of developing hypertension. JAMA 2003, 290:2945–2951. C-reactive protein levels are associated with future development of hypertension in a female middle-aged US health professional prospective cohort.PubMedCrossRefGoogle Scholar
  14. 14.
    Mervaala EM, Muller DN, Park JK, et al.: Monocyte infiltration and adhesion molecules in a rat model of high human renin hypertension. Hypertension 1999, 33:389–395.PubMedGoogle Scholar
  15. 15.
    Parissis JT, Korovesis S, Giazitzoglou E, et al.: Plasma profiles of peripheral monocyte-related inflammatory markers in patients with arterial hypertension: correlations with plasma endothelin-1. Int J Cardiol 2002, 83:13–21.PubMedCrossRefGoogle Scholar
  16. 16.
    SchiffrinEL: Role of endothelin-1 in hypertension and vascular disease. Am J Hypertens 2001, 14:83S-89S. A well-written and clear review on the role of endothelin-1 in arterial hypertension and vascular disease. Experimental and clinical data are presented.PubMedCrossRefGoogle Scholar
  17. 17.
    Bader M, Peters J, Baltatu O, et al.: Tissue renin-angiotensin systems: new insights from experimental animal models in hypertension research. J Mol Med 2001, 79:76–102.PubMedCrossRefGoogle Scholar
  18. 18.
    McFarlane SI, Kumar A, Sowers JR: Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol 2003, 91:30H-37H.PubMedCrossRefGoogle Scholar
  19. 19.
    Koh KK, Ahn JY, Han SH, et al.: Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol 2003, 42:905–910. The renin-angiotensin system may contribute to atherogenesis through the promotion of endothelial dysfunction.PubMedCrossRefGoogle Scholar
  20. 20.
    Kaysen GA, Eiserich JP: The role of oxidative stress-altered lipoprotein structure and function and microinflammation on cardiovascular risk in patients with minor renal dysfunction. J Am Soc Nephrol 2004, 15:538–548.PubMedCrossRefGoogle Scholar
  21. 21.
    Zhao Q, Ishibashi M, Hiasa KI, et al.: Essential role of vascular endothelial growth factor in angiotensin II-induced vascular inflammation and remodeling. Hypertension 2004, 44:264–270. New data on the proinflammatory activity of angiotensin II. Vascular endothelial growth factor (VEGF) is an essential mediator in Ang IIinduced vascular inflammation and structural changes through its proinflammatory actions.PubMedCrossRefGoogle Scholar
  22. 22.
    DeGrabaTJ: Expression of inflammatory mediators and adhesion molecules in human atherosclerotic plaque. Neurology 1997, 49:S15-S19.Google Scholar
  23. 23.
    NicholsTC: NF-kappaB and reperfusion injury. Drug News Perspect 2004, 17:99–104.PubMedCrossRefGoogle Scholar
  24. 24.
    Luft FC, Mervaala EM, Muller DN, et al.: Hypertension-induced end-organ damage: a new transgenic approach to an old problem. Hypertension 1999, 33:212–218.PubMedGoogle Scholar
  25. 25.
    RossR: Atherosclerosis is an inflammatory disease. Am Heart J 1999, 138:S419-S420.PubMedCrossRefGoogle Scholar
  26. 26.
    Herrmann J, Ciechanover A, Lerman LO, Lerman A: The ubiquitin-proteasome system in cardiovascular diseases: a hypothesis extended. Cardiovasc Res 2004, 61:11–21. This review summarizes recent findings regarding the ubiquitinproteasome system in cardiovascular diseases and discusses the potential use of the anti-inflammatory strategies based on proteasome inhibitors in cardiovascular therapy.PubMedCrossRefGoogle Scholar
  27. 27.
    Wojcik C, Di NapoliM: Ubiquitin-proteasome system and proteasome inhibition: new strategies in stroke therapy. Stroke 2004, 35:1506–1518. A recent review on the ubiquitin proteasome system in cerebrovascular disease.PubMedCrossRefGoogle Scholar
  28. 28.
    Di NapoliM, Papa F: Angiotensin-converting enzyme inhibitor use is associated with reduced plasma concentration of C-reactive protein in patients with first-ever ischemic stroke. Stroke 2003, 34:2922–2924.PubMedCrossRefGoogle Scholar
  29. 29.
    Ball SG, White WB: Debate: angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers: a gap in evidence-based medicine. Am J Cardiol 2003, 91:15G-21G.PubMedCrossRefGoogle Scholar
  30. 30.
    LonnE: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in atherosclerosis. Curr Atheroscler Rep 2002, 4:363–372.PubMedGoogle Scholar
  31. 31.
    Blake GJ, Ridker PM: Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med 2002, 252:283–294. How to use inflammatory markers in cardiovascular risk prediction.PubMedCrossRefGoogle Scholar
  32. 32.
    Lindsberg PJ, Grau AJ: Inflammation and infections as risk factors for ischemic stroke. Stroke 2003, 34:2518–2532.PubMedCrossRefGoogle Scholar
  33. 33.
    LoweGD: The relationship between infection, inflammation, and cardiovascular disease: an overview. Ann Periodontol 2001, 6:1–8.PubMedCrossRefGoogle Scholar
  34. 34.
    Blann AD, Ridker PM, Lip GY: Inflammation, cell adhesion molecules, and stroke: tools in pathophysiology and epidemiology? Stroke 2002, 33:2141–2143. A critical point of view on the basis of pathophysiologic mechanisms of inflammation in cerebrovascular disease. A discussion of possible targets and routes for therapeutic intervention is included.PubMedCrossRefGoogle Scholar
  35. 35.
    Tartiere JM, Henry OF, Safar H, et al.: Carotid intima-media thickness and carotid and/or iliofemoral plaques: comparison of two markers of cardiovascular risk in hypertensive patients. J Hypertens 2003, 21:739–746.PubMedCrossRefGoogle Scholar
  36. 36.
    Biasucci LM, Liuzzo G, Ciervo A, et al.: Antibody response to chlamydial heat shock protein 60 is strongly associated with acute coronary syndromes. Circulation 2003, 107:3015–3017.PubMedCrossRefGoogle Scholar
  37. 37.
    Kinjo K, Sato H, Sato H, et al.: Joint effects of Chlamydia pneumoniae infection and classic coronary risk factors on risk of acute myocardial infarction. Am Heart J 2003, 146:324–330.PubMedCrossRefGoogle Scholar
  38. 38.
    Johnston SC, Messina LM, Browner WS, et al.: C-reactive protein levels and viable Chlamydia pneumoniae in carotid artery atherosclerosis. Stroke 2001, 32:2748–2752.PubMedGoogle Scholar
  39. 39.
    Tanne D, Haim M, Boyko V, et al.: Prospective study of Chlamydia pneumoniae IgG and IgA seropositivity and risk of incident ischemic stroke. Cerebrovasc Dis 2003, 16:166–170.PubMedCrossRefGoogle Scholar
  40. 40.
    Tarnacka B, Gromadzka G, Czlonkowska A: Increased circulating immune complexes in acute stroke: the triggering role of Chlamydia pneumoniae and cytomegalovirus. Stroke 2002, 33:936–940.PubMedCrossRefGoogle Scholar
  41. 41.
    Danesh J, Whincup P, Walker M, et al.: Low-grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000, 321:199–204.PubMedCrossRefGoogle Scholar
  42. 42.
    Blankenberg S, Rupprecht HJ, Poirier O, et al.: Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003, 107:1579–1585.PubMedCrossRefGoogle Scholar
  43. 43.
    Montaner J, Alvarez-Sabin J, Barbera G, et al.: [Correlation between the expression of proinflammatory cytokines and matrix metalloproteinases in the acute phase of an ischemic stroke.] Rev Neurol 2001, 33:115–118.PubMedGoogle Scholar
  44. 44.
    Zheng Z, Lee JE, Yenari MA: Stroke: molecular mechanisms and potential targets for treatment. Curr Mol Med 2003, 3:361–372.PubMedCrossRefGoogle Scholar
  45. 45.
    BauvoisB: Transmembrane proteases in cell growth and invasion: new contributors to angiogenesis? Oncogene 2004, 23:317–329.PubMedCrossRefGoogle Scholar
  46. 46.
    de Jonge E, Dekkers PE, Creasey AA, et al.: Tissue factor pathway inhibitor does not influence inflammatory pathways during human endotoxemia. J Infect Dis 2001, 183:1815–1818.PubMedCrossRefGoogle Scholar
  47. 47.
    Di NapoliM, Papa F: Inflammation, hemostatic markers, and antithrombotic agents in relation to long-term risk of new cardiovascular events in first-ever ischemic stroke patients. Stroke 2002, 33:1763–1771.PubMedCrossRefGoogle Scholar
  48. 48.
    Tohgi H, Konno S, Takahashi S, et al.: Activated coagulation/ fibrinolysis system and platelet function in acute thrombotic stroke patients with increased C-reactive protein levels. Thromb Res 2000, 100:373–379.PubMedCrossRefGoogle Scholar
  49. 49.
    DiNapoliM: Early inflammatory response in ischemic stroke. Thromb Res 2001, 103:261–264.PubMedCrossRefGoogle Scholar
  50. 50.
    Haapaniemi E, Tatlisumak T, Soinne L, et al.: Plasminogen activator inhibitor-1 in patients with ischemic stroke. Acta Neurochir Suppl 2000, 76:277–278.PubMedGoogle Scholar
  51. 51.
    Olah L, Misz M, Kappelmayer J, et al.: Natural coagulation inhibitor proteins in young patients with cerebral ischemia. Cerebrovasc Dis 2001, 12:291–297.PubMedCrossRefGoogle Scholar
  52. 52.
    Theuma P, Fonseca VA: Inflammation and emerging risk factors in diabetes mellitus and atherosclerosis. Curr Diab Rep 2003, 3:248–254.PubMedCrossRefGoogle Scholar
  53. 53.
    Libby P, Aikawa M: Effects of statins in reducing thrombotic risk and modulating plaque vulnerability. Clin Cardiol 2003, 26:I11-I14.PubMedCrossRefGoogle Scholar
  54. 54.
    Macfelda K, Weiss TW, Kaun C, et al.: Plasminogen activator inhibitor 1 expression is regulated by the inflammatory mediators interleukin-1alpha, tumor necrosis factor-alpha, transforming growth factor-beta and oncostatin M in human cardiac myocytes. J Mol Cell Cardiol 2002, 34:1681–1691.PubMedCrossRefGoogle Scholar
  55. 55.
    McDermott MM, Green D, Greenland P, et al.: Relation of levels of hemostatic factors and inflammatory markers to the ankle brachial index. Am J Cardiol 2003, 92:194–199.PubMedCrossRefGoogle Scholar
  56. 56.
    Baidoshvili A, Nijmeijer R, Lagrand WK, et al.: Localisation of C reactive protein in infarcted tissue sites of multiple organs during sepsis. J Clin Pathol 2002, 55:152–153.PubMedGoogle Scholar
  57. 57.
    Sellmayer A, Limmert T, Hoffmann U: High sensitivity C-reactive protein in cardiovascular risk assessment: CRP mania or useful screening? Int Angiol 2003, 22:15–23.PubMedGoogle Scholar
  58. 58.
    DiNapoliM: Benefits of statins in cerebrovascular disease. Curr Opin Investig Drugs 2004, 5:295–305.PubMedGoogle Scholar
  59. 59.
    Kang SM, Chung N, Kim JY, et al.: Relation of vasodilator response of the brachial artery to inflammatory markers in patients with coronary artery disease. Echocardiography 2002, 19:661–667.PubMedCrossRefGoogle Scholar
  60. 60.
    Kimoto-Kinoshita S, Ishida S, Tomura TT: Decrease of endothelial nitric oxide synthase in stroke-prone spontaneously hypertensive rat cerebral cortex. Neurosci Lett 2000, 288:103–106.PubMedCrossRefGoogle Scholar
  61. 61.
    Kawashima S, Yamashita T, Miwa Y, et al.: HMG-CoA reductase inhibitor has protective effects against stroke events in stroke-prone spontaneously hypertensive rats. Stroke 2003, 34:157–163. The chronic treatment with statins reduce inflammatory response in stroke without reducing blood pressure levels in this stroke model.PubMedCrossRefGoogle Scholar
  62. 62.
    Christman JW, Blackwell TS, Juurlink BH: Redox regulation of nuclear factor kappa B: therapeutic potential for attenuating inflammatory responses. Brain Pathol 2000, 10:153–162.PubMedCrossRefGoogle Scholar
  63. 63.
    Di NapoliM, Papa F: The proteasome system and proteasome inhibitors in stroke: controlling the inflammatory response. Curr Opin Invest Drug 2003, 4:1333–1342.Google Scholar
  64. 64.
    ClemensJA: Cerebral ischemia: gene activation, neuronal injury, and the protective role of antioxidants. Free Radic Biol Med 2000, 28:1526–1531.PubMedCrossRefGoogle Scholar
  65. 65.
    RidkerPM: High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001, 103:1813–1818.PubMedGoogle Scholar
  66. 66.
    Horowitz GL, Beckwith BA: C-reactive protein in the prediction of cardiovascular disease. N Engl J Med 2000, 343:512–513.PubMedCrossRefGoogle Scholar
  67. 67.
    MuirKW: Inflammation, blood pressure, and stroke: an opportunity to target primary prevention? Stroke 2002, 33:2732–2733. A different point of view on the use of inflammation markers to target primary prevention.PubMedCrossRefGoogle Scholar
  68. 68.
    Yamashita T, Kawashima S, Miwa Y, et al.: A 3-hydroxy-3-methylglutaryl co-enzyme A reductase inhibitor reduces hypertensive nephrosclerosis in stroke-prone spontaneously hypertensive rats. J Hypertens 2002, 20:2465–2473.PubMedCrossRefGoogle Scholar
  69. 69.
    Reganon E, Vila V, Martinez-Sales V, et al.: Association between inflammation and hemostatic markers in atherothrombotic stroke. Thromb Res 2003, 112:217–221.PubMedCrossRefGoogle Scholar
  70. 70.
    Yu H, Rifai N: High-sensitivity C-reactive protein and atherosclerosis: from theory to therapy. Clin Biochem 2000, 33:601–610. How to use a well-defined clinical inflammation marker in cardiovascular risk prediction.PubMedCrossRefGoogle Scholar
  71. 71.
    Pepys MB, Hirschfield GM: C-reactive protein: a critical update. J Clin Invest 2003, 111:1805–1812.PubMedCrossRefGoogle Scholar
  72. 72.
    Deplanque D, Gele P, Petrault O, et al.: Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J Neurosci 2003, 23:6264–6271.PubMedGoogle Scholar

Copyright information

© Current Science Inc. 2005

Authors and Affiliations

  • Mario Di Napoli
    • 1
  • Francesca Papa
    • 1
  1. 1.Neurological SectionSMDN-Center for Cardiovascular Medicine and Cerebrovascular Disease PreventionSulmonaItaly

Personalised recommendations